Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0015 | 0 | 0.5 |
Leishmania major | pteridine reductase 1 | 0.0015 | 0 | 0.5 |
Trypanosoma brucei | pteridine reductase 1 | 0.0015 | 0 | 0.5 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0223 | 1 | 1 |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Schistosoma mansoni | 3-oxoacyl-[ACP] reductase | 0.0015 | 0 | 0.5 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0015 | 0 | 0.5 |
Trypanosoma brucei | beta-ketoacyl-ACP reductase | 0.0015 | 0 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0223 | 1 | 1 |
Trichomonas vaginalis | hypothetical protein | 0.0223 | 1 | 0.5 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0015 | 0 | 0.5 |
Schistosoma mansoni | dihydropteridine reductase | 0.0015 | 0 | 0.5 |
Leishmania major | oxidoreductase-like protein | 0.0015 | 0 | 0.5 |
Loa Loa (eye worm) | oxidoreductase | 0.0015 | 0 | 0.5 |
Loa Loa (eye worm) | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0015 | 0 | 0.5 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0223 | 1 | 1 |
Loa Loa (eye worm) | retinol dehydrogenase 12 | 0.0015 | 0 | 0.5 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0223 | 1 | 1 |
Echinococcus granulosus | 3 oxoacyl acyl carrier protein reductase | 0.0015 | 0 | 0.5 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0223 | 1 | 1 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0015 | 0 | 0.5 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0015 | 0 | 0.5 |
Entamoeba histolytica | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0015 | 0 | 0.5 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0015 | 0 | 0.5 |
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0015 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0223 | 1 | 1 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0015 | 0 | 0.5 |
Echinococcus multilocularis | 3 oxoacyl acyl carrier protein reductase | 0.0015 | 0 | 0.5 |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Leishmania major | 3-oxoacyl-ACP reductase, putative | 0.0015 | 0 | 0.5 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0223 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 5.12 uM | Inhibition of Mycobacterium tuberculosis recombinant His6-tagged InhA expressed in Escherichia coli BL21(DE3) using 2-trans-decenoyl-CoA as substrate incubated for 2 hrs prior to substrate addition by spectrophotometry | ChEMBL. | 25282650 |
Inhibition (ADMET) | = 43.79 % | Cytotoxicity against mouse RAW264.7 cells at 100 uM after 72 hrs by MTT assay | ChEMBL. | 25282650 |
Inhibition (binding) | = 82.43 % | Inhibition of Mycobacterium tuberculosis recombinant His6-tagged InhA expressed in Escherichia coli BL21(DE3) using 2-trans-decenoyl-CoA as substrate at 10 uM incubated for 2 hrs prior to substrate addition by spectrophotometry | ChEMBL. | 25282650 |
MIC (functional) | = 17.11 uM | Antimicrobial activity against extensively drug-resistant Mycobacterium tuberculosis XDR-TB after 28 days by two-fold agar dilution method | ChEMBL. | 25282650 |
Tm (binding) | = 1.9 degrees C | Inhibition of Mycobacterium tuberculosis recombinant InhA assessed as stability of protein/ligand complex measured as positive melting temperature shift by DFS technique | ChEMBL. | 25282650 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.